A DNA vaccine against extracellular domains 1-3 of flk-1 and its immune preventive and therapeutic effects against H22 tumor cell in vivo

World Journal of Gastroenterology

Volumn 10, Issue 14, 2004, Pages 2039-2044

  Lü, Fan ^a   Qin, Zhao Yin ^a   Yang, Wen Bin ^a   Qi, Yin Xin ^a   Li, Yi Min ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA VACCINE; PLASMID DNA; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXTRACELLULAR MATRIX; GENE DELIVERY SYSTEM; GENE INSERTION; GENE THERAPY; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; IN VIVO STUDY; LIVER TUMOR; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PROTEIN DOMAIN; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CELL STRAIN COS1; CHEMISTRY; DRUG EFFECT; IMMUNOLOGY; NEOPLASM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COS CELLS; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 4043175386     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i14.2039     Document Type: Article

References (38)

1. Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 2002; 23: 576-582
2. Shibuya M. Angiogenesis, anti-angiogenesis, and tumor suppression. Nippon Yakurigaku Zasshi 2002; 120: 285-294
3. Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov Today 2001; 6: 1005-1024
4. Bisacchi D, Benelli R, Vanzetto C, Ferrari N, Tosetti F, Albini A. Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. Cancer Detect Prev 2003; 27: 229-238
5. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001; 26: 25-35
6. Shibuya M. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sci 2003; 94: 751-756
7. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875-1887
8. Graff BA, Bjornaes I, Rofstad EK. Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression. Microvasc Res 2001; 61: 187-198
9. Baek JH, Jang JE, Kang CM, Chung HY, Kim ND, Kim KW. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 2000; 19: 4621-4631
10. Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S, Carbone DP. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003; 101: 4878-4886
11. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001; 23: 263-272
12. Yoshida S, Amano H, Hayashi I, Kitasato H, Kamata M, Inukai M, Yoshimura H, Majima M. COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab Invest 2003; 83: 1385-1394
13. Verheul HM, Pinedo HM. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clin Breast Cancer 2000; 1(Suppl 1): S80-84
14. Werther K, Nielsen HJ. Significance of vascular endothelial growth factor-VEGF-in tumor angiogenesis. Therapeutic possibilities in solid tumors. Ugeskr Laeger 2000; 162: 4916-4920
15. Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Nakatani T, Tsujinoue H, Fukui H. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 1999; 30: 1179-1186
16. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000; 60: 5117-5124
17. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22
18. Xiang F, Tanaka J, Takahashi J, Fukuda T. Expression of vascular endothelial growth factor (VEGF) and its two receptors in diffusely infiltrating astrocytomas and relationship to proliferative activity of tumor cells. Brain Tumor Pathol 2001; 18: 67-71
19. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M, Sato Y. Role of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 2000; 19: 2138-2146
20. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5(Suppl 1): 3-10
21. Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shibuya M. Mapping of the sites involved in ligand association and dissociation at the extracelluar domain of the kinase insert domain-containing receptor of vascular endothelial growth factor. J Biol Chem 1998; 273: 31283-31288
22. Lu D, Kussie P, Pytowski B, Persaud K, Bohlen P, Witte L, Zhu Z. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. J Biol Chem 2000; 275: 14321-14330
23. Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 2003; 82: 147-154
24. Mukherjee T, Kumar A, Mathur M, Chattopadhyay TK, Ralhan R. Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2003; 129: 430-436
25. Stockhammer G, Obwegeser A, Kostron H, Schumacher P, Muigg A, Felber S, Maier H, Slavc I, Gunsilius E, Gastl G. Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol 2000; 100: 101-105
26. Wang S, Xia T, Zhang Z, Kong X, Zeng L, Mi P, Xue Z. Expression of VEGF and tumor angiogenesis in bladder cancer. Zhonghua Waike Zazhi 2000; 38: 34-36
27. Tamura M, Ohta Y, Kajita T, Kimura K, Go T, Oda M, Nakamura H, Watanabe G. Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer. Oncol Rep 2001; 8: 1097-1102
28. Karademir S, Sokmen S, Terzi C, Sagol O, Ozer E, Astarcioglu H, Coker A, Astarcioglu I. Tumor angiogenesis as a prognostic predictor in pancreatic cancer. J Hepatobiliary Pancreat Surg 2000; 7: 489-495
29. Becker CM, Farnebo FA, Iordanescu I, Behonick DJ, Shih MC, Dunning P, Christofferson R, Mulligan RC, Taylor GA, Kuo CJ, Zetter BR. Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. Cancer Biol Ther 2002; 1: 548-553
30. Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 2002; 195: 1575-1584
31. Zhang W, Ran S, Sambade M, Huang X, Thorpe PE. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 2002; 5: 35-44
32. Shibuya M. VEGF-receptor inhibitors for anti-angiogenesis. Nippon Yakurigaku Zasshi 2003; 122: 498-503
33. Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Ided 2002; 195: 1575-1584
34. Haupt K, Roggendorf M, Mann K. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp Biol Med 2002; 227: 227-237
35. Henke A. DNA immunization - a new chance in vaccine research? Med Microbiol Immunol 2002; 191: 187-190
36. Muehlbauer PM. Anti-angiogenesis in cancer therapy. Semin Oncol Nurs 2003; 19: 180-192
37. Zogakis TG, Libutti SK. General aspects of anti-angiogenesis and cancer therapy. Expert Opin Biol Ther 2001; 1: 253-275
38. Takahashi Y, Mai M. Significance of angiogenesis and clinical application of anti-angiogenesis. Nippon Geka Gakkai Zasshi 2001; 102: 381-384